Abstract
We investigate the impact of vaccination and asymptomatic testing uptake on SARS-CoV-2 transmission in a university student population using a stochastic compartmental model. We find that the magnitude and timing of outbreaks is highly variable depending on the transmissibility of the most dominant strain of SARS CoV-2 and under different vaccine uptake levels and efficacies. When delta is the dominant strain, low level interventions (no asymptomatic testing, 30% vaccinated with a vaccine that is 80% effective at reducing infection) lead to 53-71% of students become infected during the first term. Asymptomatic testing is most useful when vaccine uptake is low: when 30% of students are vaccinated, 90% uptake of asymptomatic testing leads to almost half the case numbers. With high interventions (90% using asymptomatic testing, 90% vaccinated) cumulative incidence is 7-9%, with around 80% of these cases estimated to be asymptomatic. However, under emergence of a new variant that is at least twice as transmissible as delta and with the vaccine efficacy against infection reduced to 55%, large outbreaks are likely in universities, even with very high (90%) uptake of vaccination and 100% uptake of asymptomatic testing. If vaccine efficacy against infection against this new variant is higher (70%), then outbreaks can be mitigated if there is least 50% uptake of asymptomatic testing additional to 90% uptake of vaccination. Our findings suggest that effective vaccination is critical for controlling SARS-CoV-2 transmission in university settings with asymptomatic testing ranging from additionally useful to critical, depending on effectiveness and uptake of vaccination. Other measures may be necessary to control outbreaks under the emergence of a more transmissible variant with vaccine escape.
Competing Interest Statement
JGW has received research funding from Gilead Sciences unrelated to this research. HC is a principal investigator on a grant funded by GlaxoSmithKline unrelated to this research. All other authors declare no competing interests.
Funding Statement
HC and EBP would like to acknowledge support from the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol. HC is additionally funded through an NIHR Career Development Fellowship [CDF-2018-11-ST2-015]. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, or UKHSA. CR is a member of the MRC Integrative Epidemiology Unit and receives support from the MRC (MC_UU_00011/5) and the University of Bristol. ATh is supported by the Wellcome Trust (217509/Z/19/Z) and UKRI through the JUNIPER consortium MR/V038613/1 and CoMMinS study MR/V028545/1. EBP, EN, AB and LD are supported by UKRI through the JUNIPER consortium (Grant Number MR/V038613/1). LD and EBP are further supported by MRC (Grant Number MC/PC/19067). LD acknowledges funding from EPSRC (EP/V051555/1 and The Alan Turing Institute, Grant EP/N510129/1). DE acknowledges funding from EPSRC (EP/W000032/1). RK is funded by the Wellcome GW4 Clinical Academic Training programme (203918).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Faculty of Health Sciences Ethics Committee at the University of Bristol reviewed the study documentation and acknowledged that good ethical principles were adhered to and that the data analyzed can be used for research purposes and that the data collected can be used for publication. The study complied with the University of Bristol data protection policy for research studies (http://www.bristol.ac.uk/media-library/sites/secretary/documents/information-governance/data-protection-policy.pdf).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional analyses looking at the impacts of emergence of a new variant with increased transmissibility and reduced vaccine efficacy against infection on transmission dynamics within a university setting.
Data Availability
Contact the corresponding author regarding the data used for modelling.
